Maxis World Equity (MSCI ACWI) ETF (2559)

Overview

Pluri Inc. is a pioneering biotechnology company that has made significant advancements in the fields of regenerative medicine, food-tech, cell manufacturing, and agtech. Initially named Pluristem Therapeutics Inc., the company underwent a rebranding to Pluri Inc. in July 2022, marking a new chapter in its evolution. Founded in 2001 and headquartered in Haifa, Israel, Pluri Inc. is committed to the development and manufacture of innovative cell-based products and technologies. These developments are aimed at treating a wide range of conditions and fostering advancements in various industries. A key aspect of Pluri Inc.'s operations is its collaborative efforts, including a notable partnership with Bar-Ilan University to push forward the possibilities in cancer immunotherapy targeting solid tumors.

Products and Services

• PLX-PAD

  A cell therapy product candidate derived from maternal mesenchymal stromal cells of the placenta, intended for treating a variety of conditions. The potential applications of PLX-PAD range from aiding recovery in acute muscle injuries post-hip fractures to managing acute respiratory distress syndrome (ARDS) associated with COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia. This broad spectrum of applications showcases Pluri Inc.'s commitment to harnessing the regenerative potential of placental cells.

• PLX-R18

  Composed of fetal mesenchymal-like stromal cells from the placenta, PLX-R18 is designed to address hematopoietic complications such as those related to H-ARS. Additionally, it is undergoing a phase I trial to explore its efficacy in enhancing outcomes in hematopoietic cell transplantation. This underscores Pluri Inc.'s dedication to exploring new frontiers in cell therapy, particularly in the critical area of hematopoiesis.

• Allogeneic MAIT Cell Therapy Platform

  An innovative immunotherapy approach utilizing allogeneic mucosal-associated invariant T (MAIT) cells. This platform represents Pluri Inc.'s venture into developing cutting-edge cancer treatments and other diseases by leveraging the unique properties of MAIT cells.

• Cell Manufacturing Services

  Pluri Inc. extends its expertise in cell-based technologies to offer specialized manufacturing services. These services cater to companies and research institutions looking to scale up their cell-based product developments, reflecting Pluri Inc.'s role as a critical enabler in the broader biotech ecosystem.

• Cell-based Coffee

  In a unique convergence of biotechnology and food-tech, Pluri Inc. is also pioneering the development of cell-based coffee. This initiative signifies the company's foray into sustainable and innovative food products, aligning with global trends towards reducing environmental impact in the food industry.

• Cultivated Meat Products

  Continuing its endeavors in the food-tech sector, Pluri Inc. is developing and commercializing cultivated meat products. This represents a significant step towards creating sustainable, ethical alternatives to conventional meat, with the potential to revolutionize the way we perceive and consume animal protein.